WallStSmart

Genenta Science SpA ADR (GNTA)vs3M Company (MMM)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

MMM leads profitability with a 11.9% profit margin vs 0.0%. MMM earns a higher WallStSmart Score of 66/100 (B-).

GNTA

Avoid

23

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: -1.00

MMM

Strong Buy

66

out of 100

Grade: B-

Growth: 5.3Profit: 8.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 2.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GNTA.

MMMSignificantly Overvalued (-47.1%)

Margin of Safety

-47.1%

Fair Value

$117.53

Current Price

$177.36

$59.83 premium

UndervaluedFair: $117.53Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GNTA1 strengths · Avg: 10.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

MMM4 strengths · Avg: 8.8/10
Return on EquityProfitability
85.7%10/10

Every $100 of equity generates 86 in profit

Market CapQuality
$84.97B9/10

Large-cap with strong market position

Operating MarginProfitability
20.3%8/10

Strong operational efficiency at 20.3%

EPS GrowthGrowth
32.8%8/10

Earnings expanding 32.8% YoY

Areas to Watch

GNTA4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$30.38M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

MMM4 concerns · Avg: 3.5/10
PEG RatioValuation
1.614/10

Expensive relative to growth rate

P/E RatioValuation
29.3x4/10

Moderate valuation

Revenue GrowthGrowth
2.5%4/10

2.5% revenue growth

Price/BookValuation
31.0x2/10

Trading at 31.0x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : GNTA

The strongest argument for GNTA centers on Price/Book.

Bull Case : MMM

The strongest argument for MMM centers on Return on Equity, Market Cap, Operating Margin.

Bear Case : GNTA

The primary concerns for GNTA are Revenue Growth, EPS Growth, Market Cap.

Bear Case : MMM

The primary concerns for MMM are PEG Ratio, P/E Ratio, Revenue Growth. Debt-to-equity of 3.63 is elevated, increasing financial risk.

Key Dynamics to Monitor

MMM carries more volatility with a beta of 1.06 — expect wider price swings.

MMM is growing revenue faster at 2.5% — sustainability is the question.

MMM generates stronger free cash flow (230M), providing more financial flexibility.

Monitor CONGLOMERATES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MMM scores higher overall (66/100 vs 23/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Genenta Science SpA ADR

INDUSTRIALS · CONGLOMERATES · USA

Genenta Science SpA, a clinical-stage biotechnology company, is dedicated to the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company is headquartered in Milan, Italy.

Visit Website →

3M Company

INDUSTRIALS · CONGLOMERATES · USA

The 3M Company is an American multinational conglomerate corporation operating in the fields of industry, worker safety, US health care, and consumer goods. The company produces over 60,000 products under several brands, including adhesives, abrasives, laminates, passive fire protection, personal protective equipment, window films, paint protection films, dental and orthodontic products, electrical and electronic connecting and insulating materials, medical products, car-care products, electronic circuits, healthcare software and optical films. It is based in Maplewood, a suburb of Saint Paul, Minnesota.

Visit Website →

Want to dig deeper into these stocks?